Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome


Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)




Myelodysplastic syndrome (MDS) is a rare, potentially serious bone marrow disease. Currently available treatments for MDS have been only somewhat beneficial. The purpose of this study is to determine the effects of the medication antithymocyte globulin (ATG) in adults with MDS and to determine which individuals with MDS are most likely to benefit from treatment with ATG.

Study Status: Recruiting

Robin Heggeland, RN

Condition Intervention Phase
Myelodysplastic Syndrome Drug: Antithymocyte globulin (ATG)
Drug: Prednisone
Phase 2

Verified by Office of Rare Diseases (ORD) June, 2009

Sponsored by: Office of Rare Diseases (ORD)
Information provided by: Office of Rare Diseases (ORD) identifier: NCT00466843

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation - Case Western University
Cleveland, Ohio 44195
United States

Alan List, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site